Johnson & Johnson (JNJ) 股票分析

公司概述

Johnson & Johnson operates globally as a premier entity in the healthcare sector, specializing in the research, development, manufacturing, and sale of diverse medical products through its Innovative Medicine and MedTech segments. The company functions within the Drug Manufacturers - General industry, which encompasses the creation of pharmaceuticals and medical technologies essential for patient care and therapeutic advancements. As of the latest reporting period, the firm commands a substantial market capitalization of $581.53B, supported by an annual revenue base of $94.19B and a workforce comprising 138,200 employees. These aggregate figures underscore Johnson & Johnson's status as a dominant market player with significant scale, reflecting its ability to mobilize vast resources for global R&D initiatives and maintain extensive distribution networks across the healthcare landscape.

财务健康

The company reported a Trailing Twelve Months (TTM) revenue of $94.19B, generating a net income of $26.80B and an EBITDA of $33.84B during the period. The substantial gap between the revenue figure and the net income reveals a rigorous cost structure, where operating expenses and taxes consume approximately 71.5% of top-line sales to arrive at the final profit. Free cash flow stands at $16.63B, indicating a robust capacity to fund capital expenditures, service debt obligations, and return capital to shareholders without compromising operational liquidity. Profitability is highlighted by a Gross Margin of 68.1%, an Operating Margin of 24.0%, and a Profit Margin of 28.5%, demonstrating the company's efficiency in converting sales into earnings at every stage of the production and sales chain. Regarding leverage, the firm holds $20.10B in cash against $49.33B in debt, resulting in a Debt to Equity ratio of 60.50, which suggests a leveraged balance sheet reliant on operational cash generation to service obligations. Short-term liquidity is assessed via a Current Ratio of 1.03, indicating that current assets slightly exceed current liabilities, providing a narrow but sufficient buffer for meeting short-term financial obligations. Management effectiveness is evidenced by a Return on Equity of 35.0% and a Return on Assets of 8.7%, metrics that signify high profitability relative to the equity base and efficient utilization of total assets respectively.

估值评估

Valuation metrics indicate a Trailing Twelve Months P/E Ratio of 21.88 compared to a Forward P/E of 19.18, implying that the market expects earnings growth in the future that would lower the multiple over time. The Price to Book ratio sits at 7.13, suggesting that the market prices the company at a significant premium relative to its tangible book value, likely driven by its intangible assets and brand strength. Alternative valuation lenses such as the Price to Sales ratio of 6.17 and an EV/EBITDA of 18.05 provide context on the company's revenue efficiency and earnings power relative to enterprise value. Historical price action shows a 52-Week High of $251.71 and a 52-Week Low of $141.50, establishing a wide trading range that reflects significant price volatility over the fiscal year. The stock exhibits a Beta of 0.33, which indicates that the stock price is considerably less volatile than the broader market, offering a lower risk profile in terms of systematic price fluctuations.

Growth & Income

Growth dynamics are characterized by a Revenue Growth (YoY) of 9.1% and an Earnings Growth (YoY) of 48.6%, demonstrating that earnings are expanding at a pace significantly faster than revenue, which often points to pricing power or margin expansion in the business mix. As a consistent dividend payer, the company offers a Dividend Yield of 2.1% with a Payout Ratio of 46.6%, a level that appears sustainable given the strong earnings growth and high profit margins. The combination of double-digit earnings growth and a moderate payout ratio suggests a financial policy that balances income distribution with retention for reinvestment. Overall, the asset presents a profile combining steady revenue expansion with accelerating earnings growth and a reliable income stream via dividends, supported by a low-beta characteristic that mitigates downside risk.